Philip Morris International Inc (PM) News & Events

$191.890

+1.420 (+0.74%)At close

PM News

9.508-25CNBC

Nvidia Earnings Impact Market Dynamics

2.008-24CNBC

Steel Manufacturers Rise After Trade Negotiations Collapse

7.508-24Newsfilter

Altria and Philip Morris Enter Manufacturing Agreement

8.508-22NASDAQ.COM

Philip Morris Receives FDA Approval for New Products

8.508-21Newsfilter

PMI Receives FDA Approval for ZYN ULTRA Products

8.008-19Yahoo Finance

Comparing Dividends: Philip Morris vs. Altria

8.008-18Fool

Guide to Investing in Quality Dividend Stocks

7.008-15Fool

Alphabet Faces Legal Challenges and Financial Pressures

6.508-14Yahoo Finance

Auxier Asset Management's Latest 13F Reveals Strategic Shifts

9.508-09NASDAQ.COM

Turning Point Brands Sales Surge Over 40% from Nicotine Pouches

Show More News

PM Events

8/28 14:30

FDA Authorizes JUUL2 E-Cigarette Products for Marketing

The U.S. Food and Drug Administration authorized the marketing of three new e-cigarette products through the premarket tobacco product application pathway. The authorized products are part of the JUUL2 e-cigarette system made by JUUL Labs, which is 35% owned by Altria (M), and include a tobacco-flavored pod, a menthol-flavored pod, and the JUUL2 device. As part of its thorough scientific review of new tobacco products, the FDA considers the risks and benefits to the U.S. population as a whole - including the benefits to adults who currently use tobacco products and switch to a potentially lower-risk product, as well as the risks posed to youth and non-users of tobacco products. To receive marketing authorizations, the FDA must have sufficient evidence that the new products offer greater benefits to population health than risks. The FDA's review of data in the application found that a substantial proportion of adults who smoke completely switched away from combustible cigarettes to the authorized JUUL2 products, with the menthol-flavored pod having a higher rate of complete switching compared to the tobacco-flavored pod. Specifically, 19.9 to 34.6% of those using the tobacco-flavored pod and 28.4 to 49.3% of those using the menthol-flavored pod stopped smoking cigarettes entirely at six weeks. Those who completely switched to the authorized products were exposed to lower levels of harmful chemicals than they would have been had they continued smoking cigarettes. The FDA determined that the added benefit to adults who smoke cigarettes is sufficient to outweigh the risks of the menthol-flavored product, including youth appeal. Other publicly traded companies in the space include British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM).

8/24 07:30

Altria Group Enters Contract Manufacturing Agreement with Philip Morris USA

Altria Group (MO) announced that Philip Morris USA has entered into a contract manufacturing arrangement with non-U.S. affiliates of Philip Morris International (PM) that is intended to enhance the efficiency of PM USA's traditional tobacco product operations. The arrangement supports our 2028 Enterprise Goals by enhancing operational capabilities, generating economic benefits to support investment in our Vision and strengthening capabilities that could be transferable to our international nicotine efforts. We do not expect this arrangement will have a material impact on our 2026 financial results.

8/21 15:30

Philip Morris Receives FDA Approval for 11 ZYN ULTRA Products

Philip Morris International announced that the U.S. Food and Drug Administration issued Marketing Granted Orders to PMI's U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. "We are delighted with the FDA's decision to authorize a range of ZYN ULTRA products, which will build on ZYN's position as America's leading smoke-free product brand," said Stacey Kennedy, PMI U.S. CEO. "We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products."

7/27 08:30

Philip Morris Invests $1.2B in New Colorado Manufacturing Campus

Philip Morris International's U.S. businesses "celebrated" the opening of its Aurora, Colorado manufacturing campus, an investment representing total capital expenditures of $1.2B from 2024-2028. The campus expands the company's domestic manufacturing capabilities and positions Aurora as a strategic production and export hub supporting future growth. The site began commercial production in July 2026 and produces ZYN nicotine pouches, joining PMI U.S.'s growing modern nicotine manufacturing network, which includes operations in Owensboro, Kentucky, and Wilson, North Carolina.

7/22 12:30

Major Averages Mixed as Oil Prices Surge Again

The major averages were mixed near noon as traders take a cautious approach ahead of key earnings reports due from Alphabet, Tesla and IBM after the closing bell. Alphabet's report in particular will provide another major test of whether companies' heavy investments in artificial intelligence continue to generate meaningful returns and investors will closely scrutinize Alphabet's AI monetization strategy and cloud growth.Meanwhile, oil prices were surging once again as escalating tensions in the Middle East raise concerns over potential supply disruptions. Reports that two Saudi oil tankers altered their routes in response to Houthi threats in the Red Sea have added to fears that higher energy prices could reignite inflation pressures and complicate the Federal Reserve's policy outlook.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AT&Treportedand reiterated its FY26 outlookGE Vernovareportedand raised its FY26 revenue guidanceAMDannounced aas part of a partnership to deploy up to 2 GW of AMD Instinct GPUsRepligenBioLife Solutionsfor $31 per share, or $1.5BPhilip Morrisreportedand cut its FY26 earnings outlook2. WALL STREET CALLS:CoreWeaveto Buy at Truist after 42% pullbackPegasystemsto Market Perform at CitizensCircle Internetwith a Market Perform at Raymond JamesStifelDigitalOceanon selloff, positive data pointsTrimbleto Market Perform at Raymond James3. AROUND THE WEB:Meta'sinternal AI incubator is developing an AI model router, similar to OpenRouter's, to cut costs by sending some AI tasks to lower-cost models, The Information saysNews Corphas countersued Brave Software, alleging the company illegally scraped and sold Wall Street Journal and New York Post articles to AI companies, arguing the practice constitutes copyright infringement rather than fair use, Reuters reportsThe University of Tennessee Research Foundation sued Anthropic in Delaware federal court, arguing the company infringed its patents related to neural networks, Reuters saysPlatinum Equity is close to acquiring a 50% stake in Nestle'sEuropean water business through a joint venture that would value the San Pellegrino and Perrier owner at nearly EUR 5B, FT reportsAmgenhas reached a $74M settlement of a lawsuit accusing the company of waiting too long to disclose that it might owe the U.S. Internal Revenue Service $10.7B for underreporting six years of taxes, Reuters says4. MOVERS:Super Microgains afterArrowheadincreases after announcing its Phase 3 SHASTA-3 and SHASTA-4 studiesAirJoulehigher after announcing with Kubota Corporationanof its water-from-air technology in Texas and CaliforniaAdtranlower afterfor Q2 and Q3Dyne Therapeutics (DYN) falls after announcing a5. EARNINGS/GUIDANCE:Rogers Communications, with CEO Tony Staffieri saying the results "reflect strong execution"Moody'sand narrowed its guidance for FY26Teledyneand provided guidance for Q3 and FY26RPM, with EPS and revenue beating consensusTravel + Leisure, with CEO Michael Brown calling it "another strong quarter"INDEXES:Near midday, the Dow was up 0.33%, or 174.51, to 52,399.15, the Nasdaq was down 0.04%, or 10.89, to 25,826.32, and the S&P 500 was up 0.16%, or 11.77, to 7,520.97.

Show More Events

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.